Unapproved BPC-157 use appears to rise as human safety evidence remains scarce
Researchers say the use of unapproved peptide BPC-157 appears to be rising, but reliable information about how many people take it and its effects is scarce. The substance is promoted for injury recovery, yet most research has been in animals and evidence in humans remains limited, leaving users to take it without clear safety data or medical supervision.
A preprint study, which has not been peer reviewed, used a language model to identify mentions of BPC-157 in anonymised health records. It found about 54 confirmed users in the first quarter of 2022, rising to 1,018 in the first quarter of 2026, though the researchers say the actual number is likely higher. About a third used no other therapies or drugs, while roughly half combined it with substances including testosterone, anti-inflammatory drugs or TB-500; the study also reported that oral use was most common, followed by injections.
- Evidence on BPC-157’s safety and real-world use is limited.
- A preprint found recorded users rose from 54 to 1,018.
- Many users combine it with other substances.
New here? Start with this
BPC-157 is an unapproved substance that has become increasingly popular in fitness and wellness communities online. It is promoted for treating injuries and speeding up recovery, but it has never been approved by drug regulators and its safety and effectiveness in humans are largely unknown.
Most scientific research into BPC-157 has been carried out in animals rather than people, leaving doctors with very limited information about how it affects humans or what risks it might pose. Despite this lack of evidence, growing numbers of people are obtaining and using the substance without medical supervision, often mixing it with other drugs or supplements in untested combinations.
This means there is a significant gap between how widespread the use has become and how much is actually known about its effects and safety. Researchers and public health experts are increasingly concerned about this situation and are calling for better data on who is using the substance and what the consequences might be.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Supporters of BPC-157 access argue for personal autonomy, emphasising that adults should be permitted to make informed choices about experimental compounds, particularly when conventional medicine has failed them. They point to promising animal research and reported user benefits as meaningful preliminary evidence, and contend that overly restrictive approval processes deny access to potentially therapeutic treatments. They believe scientific literacy should be respected and individuals capable of understanding the evidence should be free to accept calculated risks.
The case against
Those concerned about BPC-157 use emphasise that the absence of human safety data represents genuine scientific uncertainty about risks, interactions, and long-term effects. They stress that medical regulation protects vulnerable people—particularly those seeking remedies whilst in pain or desperation—who may struggle to assess risks objectively. They argue that without proper trials and quality oversight, truly informed consent is impossible, and medical supervision exists specifically to prevent harm users cannot foresee.
Entertainment Health Medicine Music
Read the full article at the source →
Originally published by The Verge as “The scariest thing about gray-market peptides is how little we know”.